IGC

Insider Trades

Name	Value	Action	Price	Current Price
Moran James PDirector $200k588.2k shares BuySep 25, 2024 $0.34 --

News

accessnewswire.comAscendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalystsaccessnewswire.comJun 9

accessnewswire.comIGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysisaccessnewswire.comJun 2

accessnewswire.comIGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollmentaccessnewswire.comMay 19

accessnewswire.comIGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conferenceaccessnewswire.comMay 15

accessnewswire.comIGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phaseaccessnewswire.comApr 28

Trade IGC

About IGC Pharma, Inc.

IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.

CEO: Ram Mukunda
IPO Date: May 24, 2006

Market Data

Open: $0.273
High: $0.2849
Low: $0.273
Volume: 397.5K
Avg Volume: 1.2M
52W High: $0.50
52W Low: $0.24

Valuation

Market Cap: $28M
Enterprise Value: $28M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-6.1M
Revenue: $1.2M
Net Income: $-6.5M
Cash: $207k
Debt: $926k

Events

EarningsNov 18

EPS est. -0.02